Half-Year 2022 Financial and Clinical Trials Update
MS franchise: Ocrevus global market share reaches 21%
Fenebrutinib development programs in RMS and PPMS well on track
Roche
YoY CER growth
CHFM
+17%
Q2 update
1,500
•
+31%
1,300
•
1,100
+12%
•
+59%
900
700
•
500
300
>250.000 patients treated globally
No.1 treatment in US and EU-5
Higher persistence compared with patients treated with
other MS treatments
⚫ Ph III (OCARINA II) for Ocrevus 6-month SC dosing started
Ph III program (FENhance I/II, FENtrepid) for fenebrutinib in
RMS and PPMS well on track
Outlook 2022
100
Q2 19
US
Q2 20
Europe
Q2 21
International
Q2 22
•
US/EU: Further market share gains expected
References: 1. Pineda E, Sheinson D, Ng C, Bonine N, Pardo G. Adherence and persistence to disease-modifying therapies for multiple sclerosis and their impact on clinical and economic outcomes in a US claims database.
Presented at AAN 2021 Virtual Annual Meeting; April 17-22, 2021; CER-Constant Exchange Rates; MS-multiple sclerosis; SC=subcutaneous; RMS=relapsing MS; PPMS-primary progressive MS
28View entire presentation